Pfizer Inc. - About Lung Cancer

A new experimental drug helps shrink tumors in lung cancer patients with a specific form of genetic alteration, according to results from a clinical trial unveiled Saturday. The Pfizer Inc. drug crizotinib shrank tumors in patients with advanced non-small cell lung cancer ...

Pfizer drug shows big promise in early testing for lung cancer patients with a certain geneDoctors are reporting unusually high success rates from early tests of an experimental lung cancer drug. The drug, called crizotinib, (crih-ZAH-tin-ib), is made by Pfizer Inc. It ...

NEW YORK (Reuters) - An experimental drug being developed by Pfizer Inc that targets a specific gene mutation demonstrated impressive anti-tumor activity in patients with advanced non-small cell lung cancer (NSCLC), according to data from a small study presented on Saturday. More ...

NEW YORK (Reuters) - Pfizer Inc said on Tuesday it has ended a late-stage lung cancer study of its experimental drug figitumumab after an analysis showed it was unlikely to meet the main goal of improving overall survival. The analysis by an ...

NEW YORK (Reuters) - Pfizer Inc has halted patient enrollment in a late-stage lung cancer trial of its experimental drug, figitumumab, for safety reasons, the drugmaker said on Friday. The halt was recommended by independent safety monitors overseeing the study. In their ...

CHICAGO (Reuters) - An Abbott Laboratories Inc unit that makes genetic tests will work with Pfizer Inc to develop a test to screen non-small cell lung cancer (NSCLC) tumors to determine which patients are good candidates for a novel cancer therapy being ...

Topic: Pfizer Inc.

New lung cancer treatment shrinks some tumors: study

Lung cancer drug shows big promise in early tests

Anti-tumor impact seen with Pfizer lung cancer drug

Pfizer ends late-stage lung-cancer study

Pfizer halts enrollment in lung cancer trial

Abbott, Pfizer in pact for lung cancer screening

Photo Gallery

From Around the Web

Video Gallery

Follow this Topic with...